Abstract
Despite the ongoing pandemic and its worldwide impact, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lacks the same capacity to antagonize the type I interferon (IFN) response as its predecessor, SARS-CoV. Lokugamage et al. (e01410-20) found that SARS-CoV-2 cannot overcome type I IFN pretreatment in three different in vitro cell culture systems. Compared to the resistance observed for SARS-CoV, the results suggest that the two group 2B coronaviruses have distinct mechanisms for type I IFN antagonism.
Accepted Version
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
